knowledge -WSS

knowledge

author：focus 2025-09-03 03:45:20 - browse：652

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Some top drug companies are starting to take action on climate

knowledge

explore

WSS

Congress extends some pandemic preparedness programs

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Stop Congress from blocking public access to science

VC firm General Catalyst wants to buy a health system

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

knowledge

leisure time

Apple is now the first public company to be valued at $3 trillion

Health insurers' Q3 question: how much care are people getting?

Continuity nursing helped my family in our darkest PICU moments

Lawsuit highlights wrinkle for disputes over surprise medical bills

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Chemotherapy drug shortage eases slightly but still widespread

DIEP, the 'gold standard' of breast reconstruction, is under threat

3 questions for the future of Biden's cancer moonshot

Jerome Adams on the need for new antivirals for Covid

Bill would stop addiction treatment from triggering child abuse inquiry

hotspot

VC firm General Catalyst wants to buy a health system

Stroke deaths set to near 10 million globally by 2050

Health insurers' Q3 question: how much care are people getting?

What to expect at HLTH 2023, the health care industry conference

Colorectal cancer study finds potential in overlooked immune cell

Bristol 'take

hotspot

knowledge

explore

hotspot